Search company, investor...

Predict your next investment

Government
cancer.gov

Investments

169

Portfolio Exits

25

Partners & Customers

10

About National Cancer Institute

The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's National Cancer Institute is the principal agency for cancer research and training. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. It was founded in 1937 and is based in Bethesda, Maryland.

Headquarters Location

6116 Executive Boulevard Suite 300

Bethesda, Maryland, 20892,

United States

800-422-6237

Want to inform investors similar to National Cancer Institute about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest National Cancer Institute News

Ahead of the Curve on Head and Neck Cancers

Jan 26, 2023

UW Carbone’s expertise in head and neck cancer treatment and research are held in high esteem nationally, as evidenced by the National Cancer Institute awarding UW a Specialized Program of Research Excellence grant in 2016.

National Cancer Institute Investments

169 Investments

National Cancer Institute has made 169 investments. Their latest investment was in Vergent Bioscience as part of their Grant on November 11, 2022.

CBI Logo

National Cancer Institute Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/29/2022

Grant

Vergent Bioscience

$2M

Yes

4

11/11/2022

Grant - IV

Penn Medicine

$3.5M

No

1

11/9/2022

Grant

Kinimmune

$0.4M

Yes

3

10/21/2022

Grant

Subscribe to see more

$99M

Subscribe to see more

10

10/20/2022

Grant - III

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/29/2022

11/11/2022

11/9/2022

10/21/2022

10/20/2022

Round

Grant

Grant - IV

Grant

Grant

Grant - III

Company

Vergent Bioscience

Penn Medicine

Kinimmune

Subscribe to see more

Subscribe to see more

Amount

$2M

$3.5M

$0.4M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

1

3

10

10

National Cancer Institute Portfolio Exits

25 Portfolio Exits

National Cancer Institute has 25 portfolio exits. Their latest portfolio exit was QT Imaging on December 12, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/12/2022

Acq - Pending

$99M

1

12/2/2022

Merger

$99M

9

12/1/2022

Acquired

$99M

19

9/28/2022

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

1/17/2022

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/12/2022

12/2/2022

12/1/2022

9/28/2022

1/17/2022

Exit

Acq - Pending

Merger

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

9

19

10

10

National Cancer Institute Partners & Customers

10 Partners and customers

National Cancer Institute has 10 strategic partners and customers. National Cancer Institute recently partnered with Lantern Pharma on December 12, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

12/23/2022

Partner

United States

Lantern Pharma’s New Drug Candidate for Mantle Cell Lymphoma Shows Promise

Lantern Pharma recently published RADR-driven research , in collaboration with the National Cancer Institute , on foundational insights into how AI can be used to find new indications for cancer drugs in record times with significant reductions in costs .

1

12/15/2022

Vendor

Ireland

Accenture’s Federal Arm Wins Spot on $137M National Cancer Institute BPA for IT Services; Jill Olmstead Quoted

Accenture ` s federal business arm has won a position on a five-year , $ 137 million blanket purchase agreement with the National Cancer Institute for software engineering and information technology services .

1

11/29/2022

Partner

United States

Turnstone Biologics Enters Cooperative Research and Development Agreement with the National Cancer Institute to Study TIL Therapy in Combination with Viral Immunotherapy

`` Dr. Rosenberg pioneered cancer immunotherapy and cell therapy and we are honored to have him and the National Cancer Institute as collaborators for this study , '' said Sammy Farah , Ph.D. , M.B.A. , President and Chief Executive Officer , Turnstone Biologics Corp .

1

11/2/2022

Vendor

United States

Subscribe to see more

Subscribe to see more

10

10/18/2022

Licensee

United States

Subscribe to see more

Subscribe to see more

10

Date

12/23/2022

12/15/2022

11/29/2022

11/2/2022

10/18/2022

Type

Partner

Vendor

Partner

Vendor

Licensee

Business Partner

Country

United States

Ireland

United States

United States

United States

News Snippet

Lantern Pharma’s New Drug Candidate for Mantle Cell Lymphoma Shows Promise

Lantern Pharma recently published RADR-driven research , in collaboration with the National Cancer Institute , on foundational insights into how AI can be used to find new indications for cancer drugs in record times with significant reductions in costs .

Accenture’s Federal Arm Wins Spot on $137M National Cancer Institute BPA for IT Services; Jill Olmstead Quoted

Accenture ` s federal business arm has won a position on a five-year , $ 137 million blanket purchase agreement with the National Cancer Institute for software engineering and information technology services .

Turnstone Biologics Enters Cooperative Research and Development Agreement with the National Cancer Institute to Study TIL Therapy in Combination with Viral Immunotherapy

`` Dr. Rosenberg pioneered cancer immunotherapy and cell therapy and we are honored to have him and the National Cancer Institute as collaborators for this study , '' said Sammy Farah , Ph.D. , M.B.A. , President and Chief Executive Officer , Turnstone Biologics Corp .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

National Cancer Institute Team

2 Team Members

National Cancer Institute has 2 team members, including former Chief Information Officer, George Komatsoulis.

Name

Work History

Title

Status

George Komatsoulis

Chief Information Officer

Former

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

George Komatsoulis

Subscribe to see more

Work History

Title

Chief Information Officer

Subscribe to see more

Status

Former

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.